课题基金 / 基金详情

CALGB 90206: INTERFERON ALFA-2B OR 2B PLUS BEVACIZUMAB IN RENAL CARCINOMA

CALGB 90206: INTERFERON ALFA-2B OR 2B PLUS BEVACIZUMAB IN RENAL CARCINOMA
CALGB 90206：干扰素 ALFA-2B 或 2B 加贝伐珠单抗治疗肾癌
批准号：
7377522
负责人：
WENDY KIMRYN RATHMELL
金额：
$0.02万
依托单位：
UNIV OF NORTH CAROLINA CHAPEL HILL
依托单位国家：
美国
项目类别：
财政年份：
2005
资助国家：
美国
项目状态：
已结题
起止时间：
2005-12-01 至 2006-11-30
来源：
https://reporter.nih.gov/project-details/7377522
关键词：
CALGB90206INTERFERONALFA2B

项目摘要

项目成果

WENDY KIMRYN RATHMELL的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to compare the effects of receiving interferon alfa-2b plus the experimental agent, bevacizumab.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Career Enhancement Program
Career Enhancement Program
Career Enhancement Program
VIMORTP (Vanderbilt Integrated Molecular Oncology Research Training Program)
海外基金